CURE® Spring 2021 Issue

Doctor’s Experience as a Cancer Caregiver Is Helping Educate Others

May 10, 2021


A gynecologic oncologist who has spent her career helping patients during their cancer journeys goes a step further to educate women on how to advocate for themselves and possibly prevent cancer before it occurs.

You May Have Second Thoughts When Receiving a Cancer Diagnosis

May 07, 2021

From the Chairman

Luckily, obtaining a second opinion has become easier with advances in telehealth and other virtual technologies, which allow patients to share their medical records and test results with physicians and pathologists to potentially improve treatment plans.

Making Strides in Ovarian Cancer

May 02, 2021

Speaking Out

Clinical trials are often the key to advancements in treating ovarian cancer. As part of its “Speaking Out” video series, CURE® spoke with Dr. Debra Richardson about what patients should know about joining a trial.

Tag Teaming Liver Cancer Care

April 30, 2021

Speaking Out

As part of the “Speaking Out” video series, CURE® spoke with Dr. Laura M. Kulik about the basics of liver cancer, highlighting the need for a multidisciplinary approach to care.

Targeting a Specific Genetic Mutation May Change Treatment Landscape for Non-Small Cell Lung Cancer

April 21, 2021

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Treatments for Multiple Myeloma Are Transforming Lives

April 01, 2021

The biggest fear for many patients, according to an expert from The University of Texas MD Anderson Cancer Center, is when they hear that myeloma, for most patients, is not curable. However, she notes that every few years patient survival is increasing.

Cabometyx-Opdivo Is ‘One of the New Standards of Care’ in Treating Kidney Cancer Subtype

March 09, 2021

The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.